Overview

This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).

Eligibility

Inclusion Criteria:

• Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or
• Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.

Exclusion Criteria:

• Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),
• History of stroke,
• Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100),
• Pain (NRS ≥ 4/10),
• Pregnant or breastfeeding women,
• Patients under guardianship, curatorship, deprived of liberty, or under legal protection